PriceTargets.com logo

ArriVent BioPharma - AVBP Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $43.38
  • Forecasted Upside: 38.31%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$31.36 As of 06/17/2026 05:00 PM ET
▲ +1.03 (3.40%)

This chart shows the closing price for AVBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ArriVent BioPharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AVBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AVBP

Analyst Price Target is $43.38
▲ +38.31% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for ArriVent BioPharma in the last 3 months. The average price target is $43.38, with a high forecast of $50.00 and a low forecast of $33.00. The average price target represents a 38.31% upside from the last price of $31.36.

This chart shows the closing price for AVBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 11 polled investment analysts is to moderate buy stock in ArriVent BioPharma. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/20/2025
  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/20/2026
  • 2 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/19/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/18/2026

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/29/2026Truist FinancialBoost TargetBuy ➝ Buy$43.00 ➝ $45.00
5/22/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
5/13/2026CitigroupLower TargetBuy ➝ Buy$45.00 ➝ $43.00
5/4/2026Truist FinancialUpgradeStrong-Buy
4/24/2026CitigroupBoost TargetBuy ➝ Buy$33.00 ➝ $45.00
4/20/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
3/25/2026Truist FinancialUpgradeStrong-Buy
3/23/2026B. Riley FinancialBoost TargetBuy ➝ Buy$37.00 ➝ $45.00
3/12/2026BTIG ResearchInitiated CoverageBuy ➝ Buy$42.00
3/11/2026BTIG ResearchUpgradeStrong-Buy
3/6/2026OppenheimerReiterated RatingOutperform ➝ Outperform$44.00 ➝ $50.00
3/6/2026CitigroupBoost TargetBuy ➝ Buy$31.00 ➝ $33.00
3/6/2026HC WainwrightBoost TargetBuy ➝ Buy$42.00 ➝ $44.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Cantor FitzgeraldInitiated CoverageOverweight
12/10/2025BTIG ResearchInitiated CoverageBuy$45.00
12/10/2025BTIG ResearchInitiated CoverageBuy$45.00
12/5/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
11/25/2025Truist FinancialInitiated CoverageBuy$43.00
11/25/2025Truist FinancialInitiated CoverageBuy$43.00
11/11/2025CitigroupLower TargetBuy ➝ Buy$33.00 ➝ $31.00
10/13/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/25/2025B. Riley FinancialUpgradeStrong-Buy
8/18/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
8/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00 ➝ $42.00
8/12/2025CitigroupReiterated RatingBuy ➝ Buy$40.00 ➝ $33.00
7/22/2025HC WainwrightReiterated RatingBuy ➝ Buy$40.00
7/10/2025The Goldman Sachs GroupUpgradeBuy$33.00
6/24/2025OppenheimerReiterated RatingOutperform ➝ Outperform$39.00 ➝ $44.00
6/24/2025GuggenheimReiterated RatingBuy ➝ Buy$45.00
5/20/2025JonesTradingInitiated CoverageBuy$40.00
5/14/2025HC WainwrightBoost TargetBuy ➝ Buy$39.00 ➝ $40.00
3/20/2025B. Riley FinancialInitiated CoverageBuy$37.00
3/19/2025B. Riley FinancialUpgradeStrong-Buy
3/10/2025GuggenheimInitiated CoverageBuy$45.00
3/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$39.00 ➝ $39.00
1/22/2025HC WainwrightBoost TargetBuy ➝ Buy$36.00 ➝ $39.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
9/11/2024CitigroupBoost TargetBuy ➝ Buy$30.00 ➝ $36.00
9/10/2024OppenheimerReiterated RatingOutperform ➝ Outperform$35.00 ➝ $39.00
9/10/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$28.00 ➝ $38.00
9/10/2024HC WainwrightBoost TargetBuy ➝ Buy$30.00 ➝ $36.00
8/16/2024HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $30.00
8/15/2024OppenheimerReiterated RatingOutperform ➝ Outperform$35.00 ➝ $35.00
7/22/2024OppenheimerInitiated CoverageOutperform$35.00
6/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00
5/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$25.00
4/30/2024HC WainwrightInitiated CoverageBuy$25.00
2/20/2024Jefferies Financial GroupInitiated CoverageBuy$35.00
2/20/2024The Goldman Sachs GroupInitiated CoverageBuy$27.00
2/20/2024CitigroupInitiated CoverageBuy$30.00
(Data available from 6/18/2021 forward)

News Sentiment Rating

0.66 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2025
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2025
  • 2 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2026
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/19/2026
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/18/2026

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

ArriVent BioPharma logo
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Read More

Today's Range

Now: $31.36
Low: $30.27
High: $31.70

50 Day Range

MA: $29.10
Low: $25.19
High: $33.09

52 Week Range

Now: $31.36
Low: $16.10
High: $33.62

Volume

529,058 shs

Average Volume

558,102 shs

Market Capitalization

$1.46 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.41

Frequently Asked Questions

What sell-side analysts currently cover shares of ArriVent BioPharma?

The following Wall Street sell-side analysts have issued stock ratings on ArriVent BioPharma in the last year: B. Riley Financial, Inc., BTIG Research, Cantor Fitzgerald, Citigroup Inc., Guggenheim, HC Wainwright, Oppenheimer Holdings, Inc., The Goldman Sachs Group, Inc., Truist Financial Corporation, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for AVBP.

What is the current price target for ArriVent BioPharma?

0 Wall Street analysts have set twelve-month price targets for ArriVent BioPharma in the last year. Their average twelve-month price target is $43.38, suggesting a possible upside of 38.3%. Oppenheimer Holdings, Inc. has the highest price target set, predicting AVBP will reach $50.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $33.00 for ArriVent BioPharma in the next year.
View the latest price targets for AVBP.

What is the current consensus analyst rating for ArriVent BioPharma?

ArriVent BioPharma currently has 1 sell rating, 1 hold rating, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for AVBP.

What other companies compete with ArriVent BioPharma?

Other companies that are similar to ArriVent BioPharma include Scholar Rock, Apogee Therapeutics, CG Oncology, Grifols and Amneal Pharmaceuticals. Learn More about companies similar to ArriVent BioPharma.

How do I contact ArriVent BioPharma's investor relations team?

ArriVent BioPharma's physical mailing address is 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073, United States. The company's listed phone number is 628-277-4836 and its investor relations email address is [email protected]. The official website for ArriVent BioPharma is www.arrivent.com. Learn More about contacing ArriVent BioPharma investor relations.